TrialBMC urology2023

Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.

Roland Seiler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.